Q3 EPS Estimate for MiNK Therapeutics Boosted by Analyst

Key Points

• HC Wainwright raised MiNK Therapeutics’ Q3 2026 EPS estimate to a loss of $0.35 per share from a previous estimate of $0.63, while maintaining a Buy rating and $35 price target.
• MiNK reported a quarterly loss of $0.62 per share, narrowly missing the $0.60 consensus estimate. Analysts’ overall rating is Hold, with an average target price of $35.
• Shares opened at $11.22, near their 50-day and 200-day moving averages, while institutional ownership remains low at 2.87%; DRW Securities recently acquired a 0.55% stake.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - HC Wainwright lifted their Q3 2026 earnings estimates for shares of MiNK Therapeutics in a research note issued on Friday, August 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.35) per share for the quarter, up from their prior forecast of ($0.63). HC Wainwright currently has a "Buy" rating and a $35.00 target price on the stock. The consensus estimate for MiNK Therapeutics' current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics' Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.93) EPS, FY2027 earnings at ($1.97) EPS, FY2028 earnings at ($2.39) EPS, FY2029 earnings at ($1.67) EPS and FY2030 earnings at $0.06 EPS.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.02).

A number of other research analysts have also recently issued reports on INKT. Zacks Research cut shares of MiNK Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded MiNK Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 16th. Finally, Weiss Ratings upgraded shares of MiNK Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, July 6th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $35.00.

MiNK Therapeutics Trading Down 0.4%

Shares of NASDAQ:INKT opened at $11.22 on Tuesday. MiNK Therapeutics has a 12 month low of $8.48 and a 12 month high of $16.98. The company has a 50-day moving average price of $11.33 and a 200-day moving average price of $11.21. The company has a market cap of $55.88 million, a price-to-earnings ratio of -4.67 and a beta of 0.48.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC purchased a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 25,677 shares of the company's stock, valued at approximately $286,000. DRW Securities LLC owned 0.55% of MiNK Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 2.87% of the company's stock.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company's proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK's preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source